Achilles tendinopathy
The juxtaposition of articles on statins and Achilles tendinopathy in the October 2004 JRSM reminded me of a case relevant to the article by Maffulli and colleagues. 1 A young man was referred to me with a raised cholesterol (LDL approximately 7 mmol/L) and a family history of premature coronary heart disease. On history-taking it emerged that the patient had recently developed unilateral tendinitis, for which he had received peritendinous injections of corticosteroids. On examination he had bilateral corneal arcus and Achilles tendon xanthomata. Heterozygous familial hypercholesterolaemia was diagnosed and he was started on a statin. The association between familial hypercholesterolaemia and Achilles tendinitis is well known. 2,3 Treatment of the hypercholesterolaemia will probably lead to resolution of the tendinitis 4 but, more importantly, it may prevent a premature death. I advise looking at the eyes as well as the legs. trial. The APPROVe trial was initiated because of two previous studies 1,2 indicating that daily aspirin had protective effects against colorectal adenomas. The finding of increased risk of cardiovascular events in relation to rofecoxib did not come as a complete surprise. Such an effect was evident in the Vioxx Gastrointestinal Outcomes Research (VIGOR) 3 study, the results of which were reported almost 4 years ago. Results for the first 6 months from a similarly large trial of another selective COX-2 inhibitor, the Celecoxib Long-term Arthritis Safety Study (CLASS), 4 suggested that celecoxib had a better gastrointestinal toxicity profile than diclofenac or ibuprofen but results for the 12 month period, made available on the FDA website, 5 do not entirely support this conclusion. The discrepancy generated criticism of the way the CLASS data were initially reported. 6 Moreover, although celecoxib was not associated with a higher risk of serious cardiac sequelae than diclofenac or ibuprofen over the whole duration of the trial, the data do not exclude the possibility of lesser effects related to cardiac ischaemia.
When an unexpected drug effect is observed, whether adverse or beneficial, the possibility of a 'class-effect' has to be considered. So, might adverse cardiovascular effects be expected with COX-2 agents other than rofecoxib? This question will need to be addressed with complete transparency in future studies of COX-2 inhibitorsespecially with the advent of agents such as valdecoxib (Bextra), the successor drug of celecoxib, and etoricoxib (Arcoxia), planned successor of the withdrawn rofecoxib. Meanwhile, for the purposes of alleviating arthritic pain at least, COX-2 inhibitors have lost some of their attraction compared with the older NSAIDs such as diclofenac in combination with a proton pump inhibitor (omepraxole). 7 
